Prognostic Indicators for Breast Cancer Patients with One to Three Regional Lymph Node Metastases, with Special Reference to Alterations in Expression Levels of bcl-2, p53 and c-erbB-2 Proteins

Japanese Journal of Clinical Oncology

Volumn 27, Issue 6, 1997, Pages 371-377

  Zhang, Guo Jun ^a,b   Tsuda, Hitoshi ^a,c   Adachi, Isamu ^a   Fukutomi, Takashi ^a   Yamamoto, Hiroshi ^a   Hirohashi, Setsuo ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

bcl 2; Breast cancer; c erbB 2; P53; Prognostic indicator

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN BCL 2; PROTEIN P53;

ADULT; ARTICLE; BREAST TUMOR; CHEMISTRY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADULT; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031302528     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/27.6.371     Document Type: Article

References (38)

1. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status and survival in 14,740 breast cancer cases. Cancer 1989;63:181-7.
2. International Union Against Cancer TNM classification of malignant tumors. 4th ed. Berlin: Springer-Verlag, 1989:93-9
3. American Joint Committee on Cancer: Breast. In: Manual for staging for Breast Carcinoma. Beahrs OH, Henson DE, Hutter RVP, editors. 4th ed. Philadelphia: JB Lippincott, 1992;149.
4. Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer, 11th ed. Tokyo: Kanehara shuppan, 1992:10.
5. Nemoto T, Tominaga T, Chamberlain A, Iwasa Z, Koyama H, Hama M, et al. Differences in breast cancer between Japan and the United States. J Natl Cancer Inst 1973;58:193-7.
6. Wynder EL, Kajitani T, Kuno J Jr, Lucas JC, de Palo A, Farrow J. A comparison of survival rates between American and Japanese patients with breast cancer. Surg Gynecol Obstet 1963;117:196-200.
7. Fisher B, Slack N, Katrych D, Wolmark N. Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 1975;140:528-34.
8. Packard RA, Prosnitz LR, Bobrow SN Selection of breast cancer patients for adjuvant chemotherapy: another look at the prognostic importance of involved lymph nodes. JAMA 1977;238:1034-6.
9. Yoshimoto M, Sakamoto G, Ohashi Y. Time dependency of the influence of prognostic factors on relapse in breast cancer. Cancer 1993;72:2993-3001.
10. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. The t (14;18) chromosome translocation involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985;299:1390-3.
11. Hockenbery D, Nunez G, Milliman C, Schereiber RD. Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
12. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB et al. bcl-2 protein in non-small cell lung carcinoma. N Engl J Med 1993;329:690-4.
13. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M et al. Detection of the apoptosis-suppressmg oncoprotein Bcl-2 in hormone refractory human prostate cancers. Am J Pathol 1993;143:390-400
14. Hague A, Moorghen M, Hicks D, Chapman M, Paraskeva C. bcl-2 expression in human colorectal adenomas and carcinomas. Oncogene 1994;9:3367-70
15. Leek RD, Kaklamams L, Pezzella F, Garter KC, Harris AL. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Corner 1994;69:135-9
16. Bhargava V, Kell DL, van de Rijn M, Warnke RA. bcl-2 immunorcactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 1994;145:535-40.
17. Nathan B, Gusterson B, Jadayel D, O'Hare M, Anbazhagan R, Jayalilake H, et al. Expression of bcl-2 m primary breast cancer and its correlation of tumour phenotype. Ann Oncol 1994;5:409-14.
18. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, et al The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
19. Gasparini G, Barbareschi M, Doalioni C, Palma PD, Mann FA, Boracchi P, et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1995;1:189-98.
20. EI-Deiry WS, Tokino T, Veleulescu VE, Levy DB, Parson SR, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
21. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
22. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D. p53 expression in breast cancer. Int J Cancer 1988;41:178-83.
23. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 1991;82:835-840.
24. Thor AD, Moore II DH, Edgerton SM, Kawasaki ES, Reihsaus E. Lynch HT et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst 1992;84:845-855.
25. Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of Overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992;84:1109-14.
26. Friedrichs K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer 1993;72:3641-7.
27. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V et al. P53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 1993;85:965-70.
28. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, et al. Association of P53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-206.
29. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987:235;177-82.
30. Wright C, Angus B, Nicholson S, Sainsbury JRC, Cairns J, et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989;49:2087-90.
31. Tsuda H, Hirohashi S, Shimasato Y, Tanaka Y, Hirota T, Tsugane S, Gullick WJ, et al. Immunohistochemical study on Overexpression of c-erbB-2 protein in human breast cancer: its correlation with gene amplification and long-term survival of patients. Jpn J Cancer Res 1990;81:327-32.
32. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Watanabe S, et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma: a retrospective analysis of 176 cases. Cancer 1990;65:1794-1800.
33. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;58:457-81.
34. Gehan EA A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965;52:203-23.
35. Cox DR. Regression models and life tables. J R Stat Soc Bri 1972;34:187-220.
36. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54:2095-7.
37. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human box gene. Cell 1995;80:293-9.
38. Lipponen P, Aanltomaa S, Kosma VM, Syrjanen K. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 1994;30A:2068-73.